Kunal Nepali

2.8k total citations · 1 hit paper
66 papers, 2.1k citations indexed

About

Kunal Nepali is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Kunal Nepali has authored 66 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Molecular Biology, 21 papers in Organic Chemistry and 14 papers in Oncology. Recurrent topics in Kunal Nepali's work include Histone Deacetylase Inhibitors Research (21 papers), Peptidase Inhibition and Analysis (9 papers) and Synthesis and biological activity (7 papers). Kunal Nepali is often cited by papers focused on Histone Deacetylase Inhibitors Research (21 papers), Peptidase Inhibition and Analysis (9 papers) and Synthesis and biological activity (7 papers). Kunal Nepali collaborates with scholars based in Taiwan, India and United States. Kunal Nepali's co-authors include Jing‐Ping Liou, Hsueh‐Yun Lee, Yi-Min Liu, Ritu Ojha, Dinesh Kumar, Subheet Kumar Jain, Amandeep Thakur, Raj Kumar, Mei-Jung Lai and Fidele Ntie‐Kang and has published in prestigious journals such as Journal of Medicinal Chemistry, Molecules and International Journal of Pharmaceutics.

In The Last Decade

Kunal Nepali

64 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nitro-Group-Containing Drugs

2018 439 citations Kunal Nepali, Hsueh‐Yun Lee et al. Journal of Medicinal Chemistry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kunal Nepali Taiwan	24	1.0k	895	270	205	137	66	2.1k
Stephen Connelly United States	20	1.9k 1.9×	495 0.6×	478 1.8×	79 0.4×	37 0.3×	40	2.9k
Xuben Hou China	24	1.3k 1.2×	431 0.5×	325 1.2×	112 0.5×	45 0.3×	86	1.9k
Michael Brands Germany	20	1.1k 1.1×	601 0.7×	360 1.3×	353 1.7×	120 0.9×	46	2.1k
Jérôme Bignon France	31	1.1k 1.1×	1.8k 2.0×	386 1.4×	223 1.1×	74 0.5×	113	3.1k
Mohamed Ashraf Ali Malaysia	21	495 0.5×	877 1.0×	187 0.7×	148 0.7×	95 0.7×	136	1.8k
Peng Zhan China	23	766 0.8×	799 0.9×	179 0.7×	103 0.5×	35 0.3×	87	2.1k
Chunyong Ding China	31	1.8k 1.7×	576 0.6×	406 1.5×	194 0.9×	203 1.5×	110	3.1k
Giovanni Marzaro Italy	21	578 0.6×	609 0.7×	175 0.6×	85 0.4×	258 1.9×	80	1.4k
Bhabatarak Bhattacharyya India	24	1.2k 1.2×	673 0.8×	310 1.1×	108 0.5×	36 0.3×	57	2.0k
Giuseppe Giannini Italy	32	1.8k 1.8×	1.2k 1.3×	564 2.1×	200 1.0×	60 0.4×	95	3.0k

Countries citing papers authored by Kunal Nepali

Since Specialization

Citations

This map shows the geographic impact of Kunal Nepali's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kunal Nepali with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kunal Nepali more than expected).

Fields of papers citing papers by Kunal Nepali

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kunal Nepali. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kunal Nepali. The network helps show where Kunal Nepali may publish in the future.

Co-authorship network of co-authors of Kunal Nepali

This figure shows the co-authorship network connecting the top 25 collaborators of Kunal Nepali. A scholar is included among the top collaborators of Kunal Nepali based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kunal Nepali. Kunal Nepali is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Yuwen, Sung‐Bau Lee, Ajmer Singh Grewal, et al.. (2025). Olaparib-Cediranib Hybrid as Dual PARP-VEGFR3 Inhibitor Elicits Antitumor Efficacy: Rational Design, Synthesis, Biological Evaluation and Construction of a Charge Convertible pH Responsive Nanoformulation. Bioorganic Chemistry. 165. 109035–109035.

Singh, Hoshiyar, A. Naik, S. Basak, et al.. (2025). Anticancer activity of RM-3-22: a TAZQ-based hydroxamic acid derivative targeting NSCLC in vitro and in vivo. Frontiers in Pharmacology. 16. 1544666–1544666.

Thakur, Amandeep, et al.. (2025). Advancing glioblastoma therapy: Learning from the past and innovations for the future. Cancer Letters. 617. 217601–217601. 5 indexed citations

Chen, Ping‐Yu, Ajmer Singh Grewal, Gurpreet Singh, et al.. (2024). Rationally designed febuxostat-based hydroxamic acid and its pH-Responsive nanoformulation elicits anti-tumor activity. European Journal of Medicinal Chemistry. 279. 116866–116866. 1 indexed citations

Thakur, Amandeep, et al.. (2024). Recent advances and future directions on small molecule VEGFR inhibitors in oncological conditions. European Journal of Medicinal Chemistry. 272. 116472–116472. 13 indexed citations

Thakur, Amandeep, Yi‐Hsuan Chu, N. Vijayakameswara Rao, et al.. (2024). Leveraging a rationally designed veliparib-based anilide eliciting anti-leukemic effects for the design of pH-responsive polymer nanoformulation. European Journal of Medicinal Chemistry. 273. 116507–116507. 6 indexed citations

Lai, Mei‐Jung, Kelvin K. Tsai, Mei-Chuan Chen, et al.. (2024). Syntheses of LSD1/HDAC Inhibitors with Demonstrated Efficacy against Colorectal Cancer: In Vitro and In Vivo Studies Including Patient-Derived Organoids. Journal of Medicinal Chemistry. 67(19). 17207–17225. 5 indexed citations

Nepali, Kunal, et al.. (2023). Rationally designed donepezil-based hydroxamates modulate Sig-1R and HDAC isoforms to exert anti-glioblastoma effects. European Journal of Medicinal Chemistry. 248. 115054–115054. 10 indexed citations

Rao, N. Vijayakameswara, Chun Pan, Sung‐Bau Lee, et al.. (2022). Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier. European Journal of Medicinal Chemistry. 240. 114602–114602. 12 indexed citations

10.

Nepali, Kunal, et al.. (2022). Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal. Journal of Biomedical Science. 29(1). 65–65. 19 indexed citations

11.

Nepali, Kunal, Tsung‐I Hsu, Chien‐Ming Hsieh, et al.. (2021). Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma. European Journal of Medicinal Chemistry. 217. 113338–113338. 18 indexed citations

12.

Chang, Ting-Yu, Kunal Nepali, Yi‐Ying Chen, et al.. (2021). A novel histone deacetylase inhibitor MPT0L184 dysregulates cell-cycle checkpoints and initiates unscheduled mitotic signaling. Biomedicine & Pharmacotherapy. 138. 111485–111485. 6 indexed citations

13.

Nepali, Kunal & Jing‐Ping Liou. (2021). Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends. Journal of Biomedical Science. 28(1). 27–27. 121 indexed citations

14.

Ojha, Ritu, Kunal Nepali, Chun‐Han Chen, et al.. (2020). Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo. European Journal of Medicinal Chemistry. 190. 112086–112086. 35 indexed citations

15.

Thakur, Amandeep, Arshdeep Singh, Navdeep Kaur, Ritu Ojha, & Kunal Nepali. (2019). Steering the antitumor drug discovery campaign towards structurally diverse indolines. Bioorganic Chemistry. 94. 103436–103436. 40 indexed citations

16.

Kumar, Dinesh, Pooja Sharma, Harmanpreet Singh, et al.. (2017). The value of pyrans as anticancer scaffolds in medicinal chemistry. RSC Advances. 7(59). 36977–36999. 191 indexed citations

17.

Nepali, Kunal, Ritu Ojha, Hsueh‐Yun Lee, & Jing‐Ping Liou. (2016). Early investigational tubulin inhibitors as novel cancer therapeutics. Expert Opinion on Investigational Drugs. 25(8). 917–936. 32 indexed citations

18.

Mehndiratta, Samir, et al.. (2015). Quinazolines as Apoptosis Inducers and Inhibitors: A Review of Patent Literature. Recent Patents on Anti-Cancer Drug Discovery. 11(1). 2–66. 20 indexed citations

19.

Budhiraja, Abhishek, Sumit Arora, Kiran R. Chaudhari, et al.. (2012). Intracellular delivery of redox cycler-doxorubicin to the mitochondria of cancer cell by folate receptor targeted mitocancerotropic liposomes. International Journal of Pharmaceutics. 432(1-2). 63–74. 68 indexed citations

20.

Nepali, Kunal, Amit Agarwal, Sameer Sapra, et al.. (2011). A rational approach for the design and synthesis of 1-acetyl-3,5-diaryl-4,5-dihydro(1H)pyrazoles as a new class of potential non-purine xanthine oxidase inhibitors. Bioorganic & Medicinal Chemistry. 19(6). 1950–1958. 100 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact